COX-2 expression in ampullary carcinoma: Correlation with angiogenesis process and clinicopathological variables

Journal of Clinical Pathology

Volumn 59, Issue 5, 2006, Pages 492-496

  Perrone, G ^a   Santini, D ^a   Verzi A ^a   Vincenzi, B ^a   Borzomati, D ^a   Vecchio, F ^b   Coppola, R ^a   Antinori, A ^b   Magistrelli, P ^b   Tonini, G ^a   Rabitti, C ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYCLOOXYGENASE 2; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; VATER PAPILLA CARCINOMA;

ADULT; AGED; AMPULLA OF VATER; BIOLOGICAL MARKERS; CARCINOMA; COMMON BILE DUCT NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; STATISTICS, NONPARAMETRIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON WILLEBRAND FACTOR;

EID: 33646388248     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.030098     Document Type: Article

References (38)

1. Brennan MF. Surgical management of peripancreatic cancer. In:Bland KL, Karakousis CP, Copeland EM, editors. Altas of surgical oncology. Philadelphia: WB Saunders, 1995:473-85.
2. Klempnauer J, Ridder GJ, Pichlmayr R. Prognostic factors after resection of ampullary carcinoma: multivariate survival analysis in comparison with ductal cancer of the pancreatic head. Br J Surg 1995;82:1686-91.
3. Neoptolemos JP, Talbot IC, Shaw DC, et al. Long-term survival after resection of ampullary carcinoma is associated independently with tumor grade and a new staging classification that assesses local invasiveness. Cancer 1988;61:1403-7.
4. Roder JD, Schneider PM, Stein HJ, et al. Number of lymph node metastases is significantly associated with survival in patients with radically resected carcinoma of the ampulla of Vater. Br J Surg 1995;82:1693-6.
5. Kim HJ, Sohn TS, Lee KT, et al. Expression of cyclooxygenase-2 and its correlation with clinicopathologic factors of ampulla of Vater cancer. J Korean Med Sci 2003;18:218-24.
6. Beger HG, Treitschke F, Gansauge F, et al. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg 1999;134:526-32.
7. Bjork J, Akerbrant H, Iselius L, et al. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. Gastroenterology 2001;121:1127-35.
8. Esposito I, Friess H, Buchler MW. Carcinogenesis of cancer of the papilla and ampulla: pathophysiological facts and molecular biological mechanisms. Langenbecks Arch Surg 2001;386:163-71.
9. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
10. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
11. Thun MJ. NSAID use and decreased risk of gastrointestinal cancers. Gastroenterol Clin North Am 1996;25:333-48.
12. Ziche M, Jones J, Gullino PM. Role of prostaglandin El and copper in angiogenesis. J Natl Cancer Inst 1982;69:475-82.
13. Seed MP, Brown JR, Freemantle CN, et al. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res 1997;57:1625-9.
14. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
15. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
16. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
17. Liu LX, Lu H, Luo Y, et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun 2002;291:908-14.
18. Liu XH, Kirschenbaum A, Lu M, et al. Prostaglandin E2 induces hypoxia-inducible factor-1 alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 2002;277:50081-6.
19. Sobin LH, Wittekind C. TNM classification of malignant tumours, 6th edition. UICC International Union Against Cancer. New York: Wiley-Liss, 2002.
20. Perrone G, Vincenzi B, Santini D, et al. Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer. Cancer Lett 2004;208:227-34.
21. Soslow RA, Dannenberg AJ, Rush, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-45.
22. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
23. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6.
24. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-40.
25. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
26. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.
27. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
28. Macchiarini P, Fontanini G, Hardin MJ, et al. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992;340:145-6.
29. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-9.
30. Kolch W, Martiny-Baron G, Kieser A, et al. Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Breast Cancer Res Treat 1995;36:139-55.
31. Ferrara N, Heinsohn H, Walder CE, et al. The regulation of blood vessel growth by vascular endothelial growth factor. Ann NY Acad Sci 1995;752:246-56.
32. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
33. Inoue H, Takamori M, Shimoyama Y, et al. Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol 2002;136:287-95.
34. Mukutmoni M, Hubbard NE, Erickson KL. Prostaglandin E(2) modulation of vascular endothelial growth factor production in murine macrophages. Prostaglandins Leukot Essent Fatty Acids 2001;65:123-31.
35. Pai R, Szabo IL, Soreghan BA, et al. PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun 2001;286:923-8.
36. Eibl G, Takata Y, Boros LG, et al. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res 2005;65:982-90.
37. Paul SA, Simons JW, Mabjeesh NJ. HIF at the crossroads between ischemia and carcinogenesis. J Cell Physiol 2004;200:20-30.
38. Atiqur Rahman M, Toi M. Anti-angiogenic therapy in breast cancer. Biomed Pharmacother 2003;57:463-70.